- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
- Conditions
- Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
- Interventions
- Gilteritinib Oral Tablet, Iadademstat
- Drug
- Lead sponsor
- Oryzon Genomics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 9 more
- Conditions
- Breast Cancer
- Interventions
- Capecitabine, Dato-DXd, Eribulin, Gemcitabine, Vinorelbine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Rectal Cancer
- Interventions
- 5-Fluorouracil (5-FU), Capecitabine (Xeloda®), DRE-Endoscopy, Leucovorin, Oxaliplatin (OXAL), Quality of Life Questionnaires, intensity modulated radiotherapy (IMRT)
- Drug · Procedure · Behavioral + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 26
- States / cities
- Irvine, California • Orange, California • San Francisco, California + 22 more
- Conditions
- Rupture of Anterior Cruciate Ligament
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 1,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2030
- U.S. locations
- 47
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 39 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
- Procedure · Drug · Dietary Supplement + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 225
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
- Conditions
- Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 264
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 206 more
- Conditions
- Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms, Urologic Neoplasms, Uterine Cervical Neoplasms, Uterine Neoplasms
- Interventions
- fulvestrant, trastuzumab, tucatinib
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
- Conditions
- GERD, Obesity
- Interventions
- Endoscopy, Surgery
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 250 participants
- Timeline
- 2019 – 2028
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • New Hyde Park, New York • New York, New York + 3 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Bevacizumab, Cetuximab, Fluorouracil, Ipilimumab, Irinotecan, Leucovorin, Nivolumab, Oxaliplatin
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more
- Conditions
- Diabetes Mellitus, Type 1, Insulin Dependent Diabetes, Pregnancy in Diabetics, Pregnancy, High-Risk
- Interventions
- Hybrid closed loop insulin delivery system
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Placebo, RCT2100
- Drug · Other
- Lead sponsor
- ReCode Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 10 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- AZD5851
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 13 more
- Conditions
- Locally Advanced or Metastatic Solid Tumours
- Interventions
- AZD0171, Durvalumab, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- Mitral Regurgitation
- Interventions
- HARPOON™ Beating Heart Mitral Valve Repair System
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 5 more
- Conditions
- B-Cell Acute Lymphoblastic Leukemia
- Interventions
- CTL019
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more
- Conditions
- Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
- Interventions
- Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 91 Days to 3 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more
- Conditions
- Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Aficamten, Placebo
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
- Conditions
- AGA, Androgenetic Alopecia, Androgenetic Alopecia (AGA), Female Androgenetic Alopecia, Hair Loss
- Interventions
- Placebo, VDPHL01 BID, VDPHL01 QD
- Drug
- Lead sponsor
- Veradermics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more
- Conditions
- Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Interventions
- Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Other · Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 624
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more
- Conditions
- Progressive Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Placebo, Teriflunomide, Tolebrutinib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelofibrosis, Myeloproliferative Neoplasm, Pro-Lymphocytic Leukemia
- Interventions
- Busulfan, Cyclophosphamide, Fludarabine, Melphalan, Mesna, Mycophenolate Mofetil, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Patient Reported Outcomes, Post-Transplant Cyclophosphamide, Tacrolimus, Total-body irradiation
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 418
- States / cities
- Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more